文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

随机双盲个体化N-of-1临床试验检测TJ-68治疗肌萎缩侧索硬化症(ALS)肌肉痉挛的安全性和潜在疗效:TJ-68试验研究方案

Randomized double-blind personalized N-of-1 clinical trial to test the safety and potential efficacy of TJ-68 for treating muscle cramps in amyotrophic lateral sclerosis (ALS): study protocol for a TJ-68 trial.
PubMed 文献 · Trials · 2023-07-10

本研究为一项两中心、双盲、随机个体化N-of-1早期临床试验,计划纳入至少22例伴有每日肌肉痉挛的ALS患者,采用四周期交叉设计,每周期用药或安慰剂2周后洗脱1周。主要目的是评估TJ-68的安全性,研究对肌肉痉挛视觉模拟量表1分变化具有85%把握度。次要结局包括完整MCS评分、痉挛日记、临床总体印象变化、目标达成量表、生活质量量表和ALS功能评定量表修订版。

要点

  • TJ-68(shakuyakukanzoto)在日本ALS管理指南中被提及用于治疗ALS中难以控制的肌肉痉挛。
  • 该试验采用个体化N-of-1四周期交叉设计,每周期治疗2周后洗脱1周,主要评估安全性。
  • 研究对肌肉痉挛视觉模拟量表1分变化具有85%把握度,计划纳入至少22例每日肌肉痉挛的ALS患者。

核心结论

  • 研究正在进行中,若TJ-68被证明安全有效,则可能用于治疗ALS中的痉挛,并有助于改善和维持生活质量。

研究设计与样本

  • 两中心、双盲、随机个体化N-of-1早期临床试验,至少22例伴有每日肌肉痉挛的ALS参与者接受药物或安慰剂,采用四周期交叉设计,每治疗周期2周后洗脱1周。

主要发现

  • 主要目的为评估TJ-68的安全性,研究对肌肉痉挛影响整体日常活动的视觉模拟量表1分变化具有85%把握度。
  • 次要结局包括完整MCS评分、痉挛日记、临床总体印象变化、目标达成量表、生活质量量表和ALS功能评定量表修订版(ALSFRS-R)。

关键数值与推荐

  • 日本ALS管理指南提及TJ-68用于ALS中难以控制的肌肉痉挛。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION/AIMS: Muscle cramps are a common and often disabling symptom in amyotrophic lateral sclerosis (ALS), a devastating and incurable neurodegenerative disorder. To date, there are no medications specifically approved for the treatment of muscle cramps. Ameliorating muscle cramps in ALS may improve and sustain quality of life. A widely prescribed traditional Japanese (Kampo) medicine against muscle cramps, shakuyakukanzoto (TJ-68), has been studied in advanced liver disease, spinal stenosis, kidney failure, and diabetic neuropathy. The Japanese ALS Management Guideline mentions TJ-68 for difficult muscle cramps in ALS. Therefore, the rationale of our trial is to investigate the safety and effectiveness of TJ-68 in treating painful and disabling muscle cramps in people with ALS outside of Japan. Accordingly, we are conducting a randomized clinical trial to test the safety and efficacy of TJ-68 in participants with ALS reporting frequent muscle cramps using an innovative, personalized N-of-1 design. If successful, TJ-68 may be used for muscle cramps in a broader population of people with ALS. METHODS: This is a two-site, double-blind, randomized personalized N-of-1 early clinical trial with TJ-68. At least 22 participants with ALS and daily muscle cramps will receive drug or placebo for 2 weeks (one treatment period) followed by a 1-week washout in a four-period cross-over design. While the primary objective is to evaluate the safety of TJ-68, the study has 85% power to detect a one-point shift on the Visual Analog Scale for Muscle Cramps Affecting Overall Daily Activity of the Columbia Muscle Cramp Scale (MCS). Secondary outcomes include the full MCS score, a Cramp Diary, Clinical Global Impression of Changes, Goal Attainment Scale, quality of life scale and ALS functional rating scale-revised (ALSFRS-R). DISCUSSION: The study is underway. A personalized N-of-1 trial design is an efficient approach to testing medications that alleviate muscle cramps in rare disorders. If TJ-68 proves safe and efficacious then it may be used to treat cramps in ALS, and help to improve and sustain quality of life. TRIAL REGISTRATION: This clinical trial has been registered with ClinicalTrials.gov (NCT04998305), 8/9/2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Mitsumoto H, Cheung K, Oskarsson B, et al. Randomized double-blind personalized N-of-1 clinical trial to test the safety and potential efficacy of TJ-68 for treating muscle cramps in amyotrophic lateral sclerosis (ALS): study protocol for a TJ-68 trial. Trials. 2023. PMID: 37430314. doi:10.1186/s13063-023-07424-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。